- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Genitourinary Cancers | Clinical
Multiple Immune Cell Factors Are Associated With High Rates of Response to Nivolumab/Ipilimumab in Advanced RCC
February 19, 2022
Three immune cell-related factors appear to impact response or lack of response to treatment with nivolumab plus ipilimumab in patients with advanced or metastatic renal cell carcinoma.
Endeavoring to Achieve Deep Remissions in Prostate Cancer
February 19, 2022
Tanya Dorff, MD, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor T cells will improve outcomes.
Noteworthy Activity Observed With Frontline Avelumab in Cisplatin-Ineligible, PD-L1+ Advanced UC, Despite Missing 1-Year OS End Point
February 18, 2022
Mixed results were reported from the phase 2 ARIES clinical trial at the 2022 ASCO GU meeting.
Efficacy and Safety Findings Support Niraparib/Cabozantinib Combo in mUC and RCC
February 18, 2022
Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.
FDG and NaF PET/CT Imaging Found to Be Prognostic for Overall Survival
February 18, 2022
Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT and percent change in lesion number may be associated with overall survival in patients with metastatic genitourinary malignancies.
Upfront Avelumab Maintenance Demonstrates Continued OS Benefit in Advanced UC
February 18, 2022
An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.
Adding Lenvatinib to Pembrolizumab Does Not Extend Survival in Advanced Urothelial Carcinoma
February 18, 2022
Results from the combination of lenvatinib and pembrolizumab show similarity with the comparator in the phase 3 LEAP-011 study.
Darolutamide Sustains Safety in Metastatic Castration Resistant Prostate Cancer
February 18, 2022
Based on pooled long-term data, the safety of darolutamide is solidified in patients with metastatic castration resistant prostate cancer.
Exploring CAR T Cells in Prostate Cancer
February 18, 2022
Tanya Dorff, MD, discusses the introduction of chimeric antigen receptor T-cell therapy into the prostate cancer landscape.
Recurrence Detection Rates Appear Favorable With Novel PSMA Imaging Agent in Prostate Cancer
February 18, 2022
Utilizing 18F-rhPSMA-7.3 imaging, detection rates for prostate cancer recurrence were favorable in the phase 3 SPOTLIGHT study.